Brooks Laboratories Limited
Brooks Laboratories Limited provides contract development and manufacturing services for pharmaceutical companies in India and internationally. The company's product portfolio includes liquid injection ampoules and vials, dry powder injection vials, lyophilized injections, eye/ear drops, and nasal drops; B-Lactam and cephalosporin tablets, dry powder syrups, and injections; general, liquid, and d… Read more
Brooks Laboratories Limited - Asset Resilience Ratio
Brooks Laboratories Limited (BROOKS) has an Asset Resilience Ratio of 1.29% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2009–2025)
This chart shows how Brooks Laboratories Limited's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Brooks Laboratories Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₹299.00K | 0.02% |
| Short-term Investments | ₹17.73 Million | 1.27% |
| Total Liquid Assets | ₹18.03 Million | 1.29% |
Asset Resilience Insights
- Limited Liquidity: Brooks Laboratories Limited maintains only 1.29% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Brooks Laboratories Limited Industry Peers by Asset Resilience Ratio
Compare Brooks Laboratories Limited's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF |
Drug Manufacturers - Specialty & Generic | -0.02% |
|
Kamada
NASDAQ:KMDA |
Drug Manufacturers - Specialty & Generic | 21.63% |
|
Dongwha Pharm.Co.Ltd
KO:000020 |
Drug Manufacturers - Specialty & Generic | 1.92% |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078 |
Drug Manufacturers - Specialty & Generic | 0.46% |
|
Yuhan Corp.
KO:000100 |
Drug Manufacturers - Specialty & Generic | 0.99% |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153 |
Drug Manufacturers - Specialty & Generic | 1.81% |
|
Kotra Industries Bhd
KLSE:0002 |
Drug Manufacturers - Specialty & Generic | 9.82% |
|
Yuyu Pharma Inc
KO:000227 |
Drug Manufacturers - Specialty & Generic | 1.74% |
Annual Asset Resilience Ratio for Brooks Laboratories Limited (2009–2025)
The table below shows the annual Asset Resilience Ratio data for Brooks Laboratories Limited.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-03-31 | 1.90% | ₹23.45 Million | ₹1.24 Billion | -0.68pp |
| 2024-03-31 | 2.58% | ₹23.33 Million | ₹904.45 Million | +1.32pp |
| 2023-03-31 | 1.26% | ₹13.78 Million | ₹1.10 Billion | -0.69pp |
| 2022-03-31 | 1.94% | ₹38.10 Million | ₹1.96 Billion | +0.62pp |
| 2021-03-31 | 1.32% | ₹21.41 Million | ₹1.62 Billion | +0.35pp |
| 2020-03-31 | 0.97% | ₹15.28 Million | ₹1.58 Billion | -1.01pp |
| 2019-03-31 | 1.98% | ₹33.17 Million | ₹1.68 Billion | +1.41pp |
| 2018-03-31 | 0.56% | ₹9.67 Million | ₹1.73 Billion | +0.38pp |
| 2017-03-31 | 0.18% | ₹2.86 Million | ₹1.63 Billion | +0.12pp |
| 2010-03-31 | 0.05% | ₹200.00K | ₹372.57 Million | -0.01pp |
| 2009-03-31 | 0.06% | ₹200.00K | ₹321.19 Million | -- |